New treatment for patients with advanced melanoma

Dabrafenib (Tafinlar) is a new treatment option for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma

Melanoma: researchers assessed dabrafenib in advanced disease (Photograph: Dr P Marazzi/SPL)
Melanoma: researchers assessed dabrafenib in advanced disease (Photograph: Dr P Marazzi/SPL)

Dabrafenib inhibits V600 mutant forms of the BRAF protein. BRAF is involved in the mitogen-activated protein kinase (MAPK) pathway, which regulates the normal growth and death of cells, including skin cells. Oncogenic mutations in BRAF lead to constitutive activation of this pathway and proliferation of tumour cells.1

The most commonly observed BRAF mutation is V600E, which accounts for approximately 90% of BRAF mutations seen in melanoma.1


In the phase III BREAK-3 trial, 250 patients with BRAF V600E mutation-positive unresectable or metastatic melanoma were randomised to receive dabrafenib or dacarbazine. The primary endpoint was progression-free survival (PFS).1

In the initial analysis (median follow-up time 4.9 months), a statistically significant improvement in PFS was observed in patients treated with dabrafenib compared with those who received dacarbazine (HR 0.30, 95% CI 0.18-0.51; p<0.0001).1

In the updated analysis (median 10.5 months), a similar statistically significant improvement in median PFS was observed: 6.9 months in the dabrafenib arm compared with 2.7 months in the dacarbazine arm (HR 0.37, 95% CI 0.24-0.58; p<0.0001).1 The median overall survival was 18.2 months for dabrafenib and 15.6 months for dacarbazine (HR 0.76, 95% CI 0.48-1.21).2

The most common adverse effects with dabrafenib were hyperkeratosis, headache, pyrexia, arthralgia, fatigue, nausea, vomiting, papilloma, alopecia and rash.1

1. Tafinlar Summary of Product Characteristics, August 2013.
2. Hauschild A et al. An update on BREAK-3, a phase III, randomised trial: dabrafenib vs dacarbazine in patients with BRAF V600E positive mutation metastatic melanoma (MM). Oral abstract (#9013) presented at ASCO 2013.
Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Photodamaged skin: Identifying and managing lentigines

Photodamaged skin: Identifying and managing lentigines

Distinguishing between benign and suspect lesions is...

Survival rates in melanoma

Survival rates in melanoma

Subsequent melanomas in patients with multiple primary...

Risk of skin cancer in patients with vitiligo

Risk of skin cancer in patients with vitiligo

Patients with vitiligo have a decreased risk of melanoma...

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases